NewsEvents

Your Yourlocation: Home > Clinical observation of tiotropium bromide(136310-93-5) in the treatment of acute exacerbation of bronchial asthma

Bronchial asthma is a common respiratory disease, often acute onset of dyspnea, decreased lung function, leading to death, therefore, control of acute exacerbation of bronchial asthma is essential. Forty-eight patients with bronchial asthma were selected and treated with tiotropium bromide(136310-93-5) and tiotropium alone.

48 patients were given general treatment of asthma, phlegm, nutritional support treatment. In addition, the treatment group using twice daily airway inhalation letter must be protected.

The control group was treated with tiotropium bromide(136310-93-5) alone, once a day.

Bronchial asthma is a chronic airway inflammation, clinical manifestations of repeated wheezing, shortness of breath, chest tightness and cough-based. China's prevalence of asthma increased year by year, especially in the elderly population prevalence rate of 7% to 9%, and some patients for several years or even decades, therefore, bronchial asthma has become a heavy burden of family and society. In the presence of inflammatory mediators released by mast cells, eosinophils, and neutrophils, the airway appears to have increased responsiveness, increased secretions, and pathologic changes such as airway remodeling, limiting the reversible airflow become irreversible, so that the development of bronchial asthma into chronic obstructive pulmonary disease. Therefore, the principle of asthma treatment to expand the bronchial and anti-inflammatory treatment based.

Address: TEL:0531-82375879 Tiotropium Bromide
© Copyright(C)2014 JINAN DEXINJIA BIO & TECH CO., LTD All Rights Reserved